BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18079733)

  • 1. A prognostic score for patients with lower risk myelodysplastic syndrome.
    Garcia-Manero G; Shan J; Faderl S; Cortes J; Ravandi F; Borthakur G; Wierda WG; Pierce S; Estey E; Liu J; Huang X; Kantarjian H
    Leukemia; 2008 Mar; 22(3):538-43. PubMed ID: 18079733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
    Matsushima T; Handa H; Yokohama A; Nagasaki J; Koiso H; Kin Y; Tanaka Y; Sakura T; Tsukamoto N; Karasawa M; Itoh K; Hirabayashi H; Sawamura M; Shinonome S; Shimano S; Miyawaki S; Nojima Y; Murakami H
    Blood; 2003 May; 101(9):3386-90. PubMed ID: 12506028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International scoring system for evaluating prognosis in myelodysplastic syndromes.
    Greenberg P; Cox C; LeBeau MM; Fenaux P; Morel P; Sanz G; Sanz M; Vallespi T; Hamblin T; Oscier D; Ohyashiki K; Toyama K; Aul C; Mufti G; Bennett J
    Blood; 1997 Mar; 89(6):2079-88. PubMed ID: 9058730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes.
    Varma N; Varma S
    Indian J Pathol Microbiol; 2008; 51(1):97-101. PubMed ID: 18417875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies.
    Huang TC; Ko BS; Tang JL; Hsu C; Chen CY; Tsay W; Huang SY; Yao M; Chen YC; Shen MC; Wang CH; Tien HF
    Leukemia; 2008 Mar; 22(3):544-50. PubMed ID: 18094713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In myelodysplastic syndrome cases, what should be the level of ferritin which has prognostic value?
    Senturk Yikilmaz A; Akinci S; Bakanay ŞM; Dilek I
    Transfus Clin Biol; 2019 Nov; 26(4):217-223. PubMed ID: 31420221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system.
    Passmore SJ; Hann IM; Stiller CA; Ramani P; Swansbury GJ; Gibbons B; Reeves BR; Chessells JM
    Blood; 1995 Apr; 85(7):1742-50. PubMed ID: 7703482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Acute Myeloid Leukemia Progression on the Prognosis of 831 Patients With Myelodysplastic Syndromes From the Argentine Database.
    Enrico A; Bestach Y; Flores MG; Arbelbide J; Serale C; Novoa V; Crisp R; Rivas MM; Larripa I; Belli C
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):743-752.e5. PubMed ID: 28797621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
    Wang H; Wang XQ; Xu XP; Lin GW
    Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
    Chan GC; Wang WC; Raimondi SC; Behm FG; Krance RA; Chen G; Freiberg A; Ingram L; Butler D; Head DR
    Leukemia; 1997 Feb; 11(2):206-11. PubMed ID: 9009082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of bone marrow culturing in myelodysplastic syndrome: a retrospective analysis.
    Raymakers R; Preijers F; Boezeman J; Rutten E; De Witte T
    Leuk Lymphoma; 1994 Jun; 14(1-2):111-20. PubMed ID: 7920217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
    Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
    Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic classification and risk assessment in myelodysplastic syndromes.
    Cazzola M; Malcovati L
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):459-68. PubMed ID: 20359637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
    Tong WG; Quintás-Cardama A; Kadia T; Borthakur G; Jabbour E; Ravandi F; Faderl S; Wierda W; Pierce S; Shan J; Bueso-Ramos C; Kantarjian H; Garcia-Manero G
    Cancer; 2012 Sep; 118(18):4462-70. PubMed ID: 22252728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
    Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.